Mushtaq Mamona, Usmani Saman, Jabeen Almas, Nur-E-Alam Mohammad, Ahmed Sarfaraz, Ahmad Aftab, Ul-Haq Zaheer
Dr. Panjwani Center for Molecular Medicine and Drug Research, ICCBS,, University of Karachi, Karachi, 75270, Pakistan.
Department of Pharmacognosy, College of Pharmacy, King Saud University, P.O. Box. 2457, Riyadh, 11451, Kingdom of Saudi Arabia.
Mol Divers. 2024 Oct;28(5):2771-2782. doi: 10.1007/s11030-023-10709-4. Epub 2023 Aug 8.
A wealth of literature has highlighted the discovery of various immune modulators, frequently used in clinical practice, yet associated with numerous drawbacks. In light of this pharmacological deficiency, medical scientists are motivated to develop new immune modulators with minimized adverse effects yet retaining the improved therapeutic potential. T-cell differentiation and growth are central to human defense and are regulated by interleukin-2 (IL-2), an immune-modulatory cytokine. However, scientific investigation is hindered due to its flat binding site and widespread hotspot residues. In this regard, a prompt and logical investigation guided by integrated computational techniques was undertaken to unravel new and potential leads against IL-2. In particular, the combination of score-based and pharmacophore-based virtual screening approaches were employed, reducing the data from millions of small molecules to a manageable number. Subsequent docking and 3D-QSAR prediction via CoMFA further helped remove false positives from the data. The reliability of the model was assessed via standard metrics, which explain the model's fitness and the robustness of the model in predicting the activity of new compounds. The extensive virtual screening herein led to the identification of a total of 24 leads with potential anti-IL-2 activity. Furthermore, the theoretical findings were corroborated with in vitro testing, further endorsing the anti-inflammatory potential of the identified leads.
大量文献强调了各种免疫调节剂的发现,这些调节剂在临床实践中经常使用,但存在许多缺点。鉴于这种药理学缺陷,医学科学家们致力于开发新的免疫调节剂,使其副作用最小化,同时保留提高的治疗潜力。T细胞分化和生长是人体防御的核心,受免疫调节细胞因子白细胞介素-2(IL-2)调控。然而,由于其扁平的结合位点和广泛分布的热点残基,科学研究受到阻碍。在这方面,我们进行了一项由综合计算技术指导的迅速而合理的研究,以揭示针对IL-2的新的潜在先导化合物。特别是,采用了基于评分和基于药效团的虚拟筛选方法相结合的方式,将数百万个小分子的数据减少到可管理的数量。随后通过CoMFA进行对接和3D-QSAR预测,进一步帮助从数据中去除假阳性。通过标准指标评估了模型的可靠性,这些指标解释了模型的拟合度以及模型在预测新化合物活性方面的稳健性。本文广泛的虚拟筛选共鉴定出24种具有潜在抗IL-2活性的先导化合物。此外,理论研究结果得到了体外测试的证实,进一步支持了所鉴定先导化合物的抗炎潜力。